CTOs on the Move

Virtus Pharmaceuticals

www.virtusrx.com

 
Virtus Pharmaceuticals’ mission is to be the leading specialty niche pharmaceutical company providing the highest quality products through experienced leadership, innovative approaches and outstanding customer service.
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.virtusrx.com
  • 2649 Causeway Center Drive
    Tampa, FL USA 33619
  • Phone: 813.283.1344

Executives

Name Title Contact Details

Similar Companies

Neopharm Labs

As a trusted partner to leaders in the pharmaceutical and life sciences industry for over 30 years, we`ve built a reputation for quality, problem‑solving capabilities, and a superior customer experience. We`re proud to play an integral role in bettering the lives of the global community.

Imagine Pharma

Imagine Pharma is a drug discovery and development company that focuses on innovative approaches to therapeutic drugs for diabetes and cardiovascular disease. Our agile, creative and efficient approach to drug discovery is designed to find therapeutics that significantly improve on the efficacy and safety of existing treatments.

Shimadzu

Shimadzu Corporation is a Japanese public KK company, manufacturing precision instruments, measuring instruments and medical equipment, based in Kyoto, Japan.

KaVo Kerr

KaVo Kerr is a dental equipment manufacturer group that was spun off from Danaher Corporation.

Opko

OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.